Dominick Auci
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$14.6MFederal grants as PI17 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
17 awards · $14.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Apr 11, 2025 | NIH | SBIR Phase II IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis | $960K | THERAPYX, INC. |
| Mar 25, 2024 | NIH | SBIR Phase II IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis | $960K | THERAPYX, INC. |
| May 31, 2023 | NIH | SBIR Phase II IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis | $1.2M | THERAPYX, INC. |
| Jun 8, 2022 | NIH | SBIR Phase II Experimental Gonococcal Vaccine | $1.0M | THERAPYX, INC. |
| Apr 25, 2022 | NIH | SBIR Phase II Therapy and Prophylaxis for Genital Tract Infection | $915K | THERAPYX, INC. |
| Jun 29, 2021 | NIH | SBIR Phase II Experimental Gonococcal Vaccine | $1.0M | THERAPYX, INC. |
| Apr 23, 2021 | NIH | SBIR Phase II Therapy and Prophylaxis for Genital Tract Infection | $1.0M | THERAPYX, INC. |
| Mar 8, 2021 | NIH | SBIR Phase II IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis | $848K | THERAPYX, INC. |
| Jul 15, 2020 | NIH | SBIR Phase II Experimental Gonococcal Vaccine | $807K | THERAPYX, INC. |
| May 1, 2020 | NIH | SBIR Phase II Therapy and Prophylaxis for Genital Tract Infection | $1.0M | THERAPYX, INC. |
| Feb 27, 2020 | NIH | SBIR Phase II IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis | $858K | THERAPYX, INC. |
| May 31, 2019 | NIH | SBIR Phase II Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD | $1000K | THERAPYX, INC. |
| Mar 7, 2019 | NIH | SBIR Phase II IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis | $389K | THERAPYX, INC. |
| Jul 1, 2018 | NIH | SBIR Phase I PLGA encapsulated polyphenols to ameliorate IBD. | $320K | THERAPYX, INC. |
| Apr 30, 2018 | NIH | SBIR Phase II Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD | $1000K | THERAPYX, INC. |
| Jun 20, 2017 | NIH | SBIR Phase II Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD | $1000K | THERAPYX, INC. |
| Sep 5, 2016 | NIH | SBIR Phase I Oral sustained-release IL-10 microspheres for therapy of IBD | $296K | THERAPYX, INC. |
Peer ranks
Federal funding#19
Awards as PI#29
Patents#273
Companies
- THERAPYX, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.